C-QAKXAltay Therapeutics
transcription factor inhibition, small molecules, allosteric sites
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-QAKX
C-QAKXC-QAKXtranscription factor inhibition, small molecules, allosteric sites
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Altay Therapeutics transcription factor inhibition, small molecules, allosteric sites
Altay Therapeutics is a small US startup developing oral small-molecule transcription factor inhibitors, with its clearest disease-specific claim centered on DUX4 inhibition for facioscapulohumeral muscular dystrophy (FSHD) and additional company-claimed programs in STAT3-driven fibrosis/inflammation and oncology. The project is potentially important because FSHD has serious unmet need and oral small molecules would be easier to scale and deliver than gene-targeting approaches, but the evidence here is still thin: most efficacy, selectivity, and timeline claims are company-authored, with patents, SBIR summaries, grant profiles, and prize recognition providing traction signals rather than independent validation.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Altay Therapeutics — Early mechanism · Bottom quartile. Derived deterministically from 8 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical).…
Source: Deterministic